Role of Steroids in the Management of Diabetic Macular Edema and Proliferative Diabetic Retinopathy

REFERENCES

• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047–1053
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National diabetes fact sheet: General information and national estimates on diabetes in the United States, 2007. U. S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA 2008
   Google Scholar
• Klein R, Klein B E. Vision disorders. Diabetes in America, M WH Harrris, Bethesda, MD 1995; 293–338, NIH-NIDDK Publication No. 95–1468
   Google Scholar
• Kempen J H, O'Colmain B J, Leske M C, Haffner S M, Klein R, Moss S E, Taylor H R, Hamman R F. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122: 552–563
   PubMed Web of Science ®Google Scholar
• Beetham W P, Aiello L M, Balodimos M C, Koncz L. Ruby-laser photocoagulation of early diabetic neovascular retinopathy: Preliminary report of a long-term controlled study. Trans Am Ophthalmol Soc 1969; 67: 39–67
   PubMedGoogle Scholar
• Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol 1976; 81: 383–396
   Google Scholar
• Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98: 766–785
   PubMed Web of Science ®Google Scholar
• Chew E Y, Ferris F L, III, Csaky K G, Murphy R P, Agron E, Thompson D J, Reed G F, Schachat A P. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: The early treatment diabetic retinopathy follow-up study. Ophthalmology 2003; 110: 1683–1689
   PubMed Web of Science ®Google Scholar
• Klein R, Klein B E, Moss S E, Davis M D, DeMets D L. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984; 91: 1464–1474
   PubMed Web of Science ®Google Scholar
• Ferris F L, III, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 1984; 28(Suppl)452–461
   PubMed Web of Science ®Google Scholar
• Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103: 1796–1806
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Focal/Grid Photocoagulation for Diabetic Macular Edema. Ophthalmology 2008; 115: 1447–1449
   PubMed Web of Science ®Google Scholar
• Browning D J, Glassman A R, Aiello L P, Beck R W, Brown D M, Fong D S, Bressler N M, Danis R P, Kinyoun J L, Nguyen Q D, Bhavsar A R, Gottlieb J, Pieramici D J, Rauser M E, Apte R S, Lim J I, Miskala P H. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007; 114: 525–536
   PubMed Web of Science ®Google Scholar
• Browning D J, Altaweel M M, Bressler N M, Bressler S B, Scott I U. Diabetic macular edema: What is focal and what is diffuse?. Am J Ophthalmol 2008; 146: 649–55; 655
   PubMedGoogle Scholar
• Danis R P, Glassman A R, Aiello L P, Antoszyk A N, Beck R W, Browning D J, Ciardella A P, Kinyoun J L, Murtha T J, Topping T M, Shami M, Sharuk G S, Wells J A, III. Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema. Arch Ophthalmol 2006; 124: 1701–1707
   PubMedGoogle Scholar
• Joussen A M, Smyth N, Niessen C. Pathophysiology of diabetic macular edema. Dev Ophthalmol 2007; 39: 1–12
   PubMedGoogle Scholar
• Aiello L P, Cahill M T, Wong J S. Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol 2001; 132: 760–766
   PubMed Web of Science ®Google Scholar
• Joussen A M. Therapeutic approaches to (diabetic) macular edema. Retinal Vascular Disease., A. M. Joussen, T W Gardner, B. Kirchhof, S J Ryan. Springer-Verlag, HeidelbergGermany 2007; 353–376
   Google Scholar
• Antonetti D A, Barber A J, Hollinger L A, Wolpert E B, Gardner T W. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999; 274: 23463–23467
   PubMed Web of Science ®Google Scholar
• Schroder S, Palinski W, Schmid-Schonbein G W. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 1991; 139: 81–100
   PubMed Web of Science ®Google Scholar
• Kern T S. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007; 2007: 95103
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Khosrof S, Bursell S E, Rohan R, Murata T, Clermont A C, Aiello L P, Ogura Y, Adamis A P. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 1999; 96: 10836–10841
   PubMed Web of Science ®Google Scholar
• Joussen A M, Poulaki V, Mitsiades N, Cai W Y, Suzuma I, Pak J, Ju S T, Rook S L, Esser P, Mitsiades C S, Kirchhof B, Adamis A P, Aiello L P. Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J 2003; 17: 76–78
   PubMed Web of Science ®Google Scholar
• Miller J W, Adamis A P, Shima D T, D'Amore P A, Moulton R S, O'Reilly M S, Folkman J, Dvorak H F, Brown L F, Berse B. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145: 574–584
   PubMed Web of Science ®Google Scholar
• Aiello L P, Bursell S E, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla T A, Ways K, Jirousek M, Smith L E, King G L. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46: 1473–1480
   PubMed Web of Science ®Google Scholar
• Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984; 101: 527–537
   PubMed Web of Science ®Google Scholar
• Vlassara H. Recent progress on the biologic and clinical significance of advanced glycosylation end products. J Lab Clin Med 1994; 124: 19–30
   PubMed Web of Science ®Google Scholar
• Mclean J M, Gordon D M, Koteen H. Clinical experiences with ACTH and cortisone in ocular diseases. Trans Am Acad Ophthalmol Otolaryngol 1951; 55: 565–572
   PubMedGoogle Scholar
• Jabs D A, Rosenbaum J T, Foster C S, Holland G N, Jaffe G J, Louie J S, Nussenblatt R B, Stiehm E R, Tessler H, Van Gelder R N, Whitcup S M, Yocum D. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000; 130: 492–513
   PubMed Web of Science ®Google Scholar
• Folkman J, Langer R, Linhardt R J, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983; 221: 719–725
   PubMed Web of Science ®Google Scholar
• Jonas J B, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res 2005; 24: 587–611
   PubMed Web of Science ®Google Scholar
• Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985; 230: 1375–1378
   PubMed Web of Science ®Google Scholar
• Ingber D E, Madri J A, Folkman J. A possible mechanism for inhibition of angiogenesis by angiostatic steroids: Induction of capillary basement membrane dissolution. Endocrinology 1986; 119: 1768–1775
   PubMed Web of Science ®Google Scholar
• Folkman J, Ingber D E. Angiostatic steroids. Method of discovery and mechanism of action. Ann Surg 1987; 206: 374–383
   PubMed Web of Science ®Google Scholar
• Clark A F. Mechanism of action of the angiostatic cortisene anecortave acetate. Surv Ophthalmol 2007; 52(Suppl 1)S26–S34
   PubMed Web of Science ®Google Scholar
• D'Amico D J, Goldberg M F, Hudson H, Jerdan J A, Krueger S, Luna S, Robertson S M, Russell S, Singerman L, Slakter J S, Sullivan E K, Yannuzzi L, Zilliox P. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): Interim (month 6) analysis of clinical safety and efficacy. Retina 2003; 23: 14–23
   PubMed Web of Science ®Google Scholar
• Slakter J S, Bochow T W, D'Amico D J, Marks B, Jerdan J, Sullivan E K, Robertson S M, Slakter J S, Sullins G, Zilliox P. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006; 113: 3–13
   PubMed Web of Science ®Google Scholar
• Alcon Terminates the Development of Anecortave Acetate in Age-Related Macular Degeneration. 2008, Alcon Laboratories Press Release Archive: July 11
   Google Scholar
• Yannuzzi L A. Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg). 2007, ClinicalTrials giv Identifier: NCT00211406
   Google Scholar
• Yannuzzi L A. Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension (15 mg). 2007, ClinicalTrials gov Identifier: NCT00211471
   Google Scholar
• Nauck M, Karakiulakis G, Perruchoud A P, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998; 341: 309–315
   PubMed Web of Science ®Google Scholar
• Jonas J B, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001; 132: 425–427
   PubMed Web of Science ®Google Scholar
• Martidis A, Duker J S, Greenberg P B, Rogers A H, Puliafito C A, Reichel E, Baumal C. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109: 920–927
   PubMed Web of Science ®Google Scholar
• Grover D, Li T J, Chong C C. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev 2008, CD005656
   Google Scholar
• Ockrim Z K, Sivaprasad S, Falk S, Roghani S, Bunce C, Gregor Z, Hykin P. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. Br J Ophthalmol 2008; 92: 795–799
   PubMed Web of Science ®Google Scholar
• Massin P, Audren F, Haouchine B, Erginay A, Bergmann J F, Benosman R, Caulin C, Gaudric A. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: Preliminary results of a prospective controlled trial. Ophthalmology 2004; 111: 218–224
   PubMed Web of Science ®Google Scholar
• Gillies M C, Sutter F K, Simpson J M, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: Two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006; 113: 1533–1538
   PubMed Web of Science ®Google Scholar
• Audren F, Erginay A, Haouchine B, Benosman R, Conrath J, Bergmann J F, Gaudric A, Massin P. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 2006; 84: 624–630
   PubMedGoogle Scholar
• Chew E, Strauber S, Beck R, Aiello L P, Antoszyk A, Bressler N, Browning D, Danis R, Fan J, Flaxel C, Friedman S, Glassman A, Kollman C, Lazarus H. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: A pilot study. Ophthalmology 2007; 114: 1190–1196
   PubMed Web of Science ®Google Scholar
• Entezari M, Ahmadieh H, Dehghan M H, Ramezani A, Bassirnia N, Anissian A. Posterior sub-tenon triamcinolone for refractory diabetic macular edema: A randomized clinical trial. Eur J Ophthalmol 2005; 15: 746–750
   Google Scholar
• Browning D J, Glassman A R, Aiello L P, Beck R W, Brown D M, Fong D S, Bressler N M, Danis R P, Kinyoun J L, Nguyen Q D, Bhavsar A R, Gottlieb J, Pieramici D J, Rauser M E, Apte R S, Lim J I, Miskala P H. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007; 114: 525–536
   PubMed Web of Science ®Google Scholar
• Faghihi H, Roohipoor R, Mohammadi S F, Hojat-Jalali K, Mirshahi A, Lashay A, Piri N, Faghihi S. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 2008; 18: 941–948
   PubMed Web of Science ®Google Scholar
• Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan M H, Azarmina M, Moradian S, Tabatabaei H, Peyman G A. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007; 27: 1187–1195
   PubMed Web of Science ®Google Scholar
• Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, Soheilian M, Keshavarzi G, Mohebbi M R. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; A placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008; 246: 483–489
   PubMed Web of Science ®Google Scholar
• Lam D S, Chan C K, Mohamed S, Lai T Y, Lee V Y, Liu D T, Li K K, Li P S, Shanmugam M P. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: Six-month outcomes. Ophthalmology 2007; 114: 2162–2167
   PubMed Web of Science ®Google Scholar
• Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005; 140: 695–702
   PubMed Web of Science ®Google Scholar
• Kang S W, Sa H S, Cho H Y, Kim J I. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 2006; 124: 653–658
   PubMed Web of Science ®Google Scholar
• Beck R W, Glassman A R. Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema (LRT for DME). 2008, ClinicalTrials gov Identifier: NCT00444600
   Google Scholar
• Gillies M C, Zhu M. A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema. 2008, ClinicalTrials gov Identifier: NCT00148265
   Google Scholar
• Beck R W, Glassman A R. Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy (LRTforDME+PRP). 2008, ClinicalTrials gov Identifier: NCT00445003
   Google Scholar
• Wilson C A, Berkowitz B A, Sato Y, Ando N, Handa J T, de Juan E, Jr. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992; 110: 1155–1159
   PubMed Web of Science ®Google Scholar
• Zein W M, Noureddin B N, Jurdi F A, Schakal A, Bashshur Z F. Panretinal photocoagulation and intravitreal triamcinolone acetonide for the management of proliferative diabetic retinopathy with macular edema. Retina 2006; 26: 137–142
   Web of Science ®Google Scholar
• Bandello F, Polito A, Pognuz D R, Monaco P, Dimastrogiovanni A, Paissios J. Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy. Arch Ophthalmol 2006; 124: 643–650
   PubMedGoogle Scholar
• Kaderli B, Avci R, Gelisken O, Yucel A A. Intravitreal triamcinolone as an adjunct in the treatment of concomitant proliferative diabetic retinopathy and diffuse diabetic macular oedema. Combined IVTA and laser treatment for PDR with CSMO. Int Ophthalmol 2005; 26: 207–214
   PubMedGoogle Scholar
• Choi K S, Chung J K, Lim S H. Laser photocoagulation combined with intravitreal triamcinolone acetonide injection in proliferative diabetic retinopathy with macular edema. Korean J Ophthalmol 2007; 21: 11–17
   Google Scholar
• Maia O O, Jr., Takahashi B S, Costa R A, Scott I U, Takahashi W Y. Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: One-year results of a randomized clinical trial. Am J Ophthalmol 2009; 147: 291–297
   PubMed Web of Science ®Google Scholar